Panacea Biotec Ltd has received a prestigious order worth $4.75 million to supply vaccines. The contract underscores the company’s growing footprint in vaccine manufacturing and its commitment to supporting international immunization efforts with high-quality, WHO-prequalified vaccines, advancing global health outcomes.
Panacea Biotec Limited announced it has been awarded a significant supply contract valued at $4.75 million for vaccines. The order highlights the company’s leadership in developing and manufacturing high-quality vaccines, including liquid combination vaccines that can be stored efficiently at low temperatures. This newer contract complements Panacea’s existing portfolio that includes multiple pediatric vaccines such as EasySix, EasyFive-TITM, and oral polio vaccine variants.
The company continues to expand its global reach by partnering with international health organizations and governments to combat vaccine-preventable diseases, particularly in developing countries. Panacea Biotec’s stringent adherence to WHO standards underscores its commitment to patient safety and effective disease control.
This supply order contributes to Panacea’s long-term growth outlook and reinforces its position as a reliable vaccine supplier in a competitive global landscape. Ongoing investments in research, development, and manufacturing capabilities remain core to Panacea’s strategy to innovate and meet global immunization needs.
Key Highlights:
-
Vaccine supply order valued at $4.75 million (approx ₹19 crore).
-
Contract expands Panacea’s footprint in global vaccine manufacturing market.
-
Portfolio includes combination vaccines and oral polio vaccines meeting WHO standards.
-
Strengthens partnerships with international health organizations.
-
Reinforces commitment to addressing vaccine-preventable diseases in developing countries.
-
Supports sustainable growth driven by innovation and quality manufacturing.
Sources: MarketScreener, Panacea Biotec official website, Reuters, CNBC-TV18